A study published in *Nature Immunology* by researchers at Boston Children's Hospital reveals a promising new strategy to enhance COVID-19 vaccination. By pairing the original mRNA vaccine with an innovative adjuvant called 'mannadjuvant,' derived from mannan—a sugar molecule from the yeast *Candida*—the team extended the vaccine's protective duration in mice from a few months to as long as two years. This method not only prolonged immunity but also elicited a stronger immune response against omicron variants compared to the mRNA vaccine alone. Ivan Zanoni, PhD, who led the research, emphasized that this approach could potentially eliminate the need for frequent boosters, which are often required due to waning antibody levels and rapid viral mutations. The researchers ensured the stability of the vaccine when combined with the adjuvant and conducted tests that confirmed its efficacy. Following these promising results, the team has filed patents for the mannadjuvant and launched a biotech spinoff to advance its development toward human trials. Further investigations will focus on understanding how the mannadjuvant stimulates the immune system, particularly in response to fungal components.